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Introduction
As  a  consequence  of  great  advances  in  the  pharmacological  environment,  in  the  devices
used,  and  in  reﬁnements  in  technique,  PCI  has  become  the  most  common  form  of  coro-
nary  revascularization.  The  main  limitation  of  PCI  is  EST  (i.e.  within  30  days  post  PCI)—a
rare  (0.75—2%)  but  deadly  event.  Investigations  aimed  at  identifying  biomarkers  for  these
complications  have  focused  on  markers  of  platelet  activation,  as  assessed  by  PR  inhibi-
tion  [1].  In-stent  restenosis,  on  the  other  hand,  is  a  frequent  complication  of  bare-metal
stent  implantation,  occurring  within  3  to  6  months  after  PCI  and  with  a  high  morbidity.
It  is  a  complex  phenomenon  involving  several  players.  Early  regeneration  of  the  injured
endothelial  monolayer  is  key  to  prevent  in-stent  restenosis  [2].  Since  EPC  were  identiﬁed
recently  in  the  peripheral  blood  of  adults,  studies  have  demonstrated  that  their  role  is
critical  for  the  repair  processes  [3].  Endothelial  biomarkers  reﬂecting  injury  and  repair
potential  could  therefore  be  of  interest  to  identify  patients  at  risk  of  in-stent  restenosis.Plaquettes  ;
Resténose  ;
Thrombose
Early stent thrombosis
Early  stent  thrombosis  is  a  multifactorial  process;  factors  responsible  for  this  complication
are  related  to  the  patient,  the  lesion  and  the  procedure.  The  development  of  antiplatelet
Abbreviations: EPC, Endothelial Progenitor Cells; PCI, Percutaneous Coronary Intervention; PR, Platelet Reactivity; VASP,
Vasodilator-Stimulated Phosphoprotein; EST, Early Stent Thrombosis.
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gents  has  been  critical  to  reduce  the  rate  of  early  stent
hrombosis  following  PCI.  The  addition  of  thienopyridines
o  aspirin  has  dramatically  reduced  the  rate  of  EST  from
0  to  15%  to  less  than  3%  [4].  Iakovou  et  al.  [5]  observed
 hazard  ratio  of  151  for  stent  thrombosis  in  the  case
f  premature  discontinuation  of  antiplatelet  therapy,  thus
nderlining  the  key  role  of  these  agents.  However,  inves-
igators  observed  wide  inter-individual  variability  in  the
iological  efﬁcacy  of  clopidogrel.  This  variability  is  related
o  several  factors,  including  genetic,  clinical  and  cellular
lements.  The  biological  efﬁcacy  of  clopidogrel  is  therefore
npredictable.  Several  platelet  assays  have  been  devel-
ped  to  overcome  the  limitations  of  aggregometry,  including
echnical  requirements,  lack  of  standardization  and  lack
f  speciﬁcity  [6].  Since  then,  the  literature  has  demon-
trated  that  the  biological  variability  in  the  response  to
lopidogrel  is  associated  with  the  occurrence  of  recurrent
hrombotic  events  and  in  particular  early  stent  thrombo-
is.  Although  these  studies  were  performed  with  various
latelet  assays,  they  consistently  observed  a  strong  associ-
tion  between  high  on-treatment  PR  and  thrombotic  events
fter  PCI.  In  addition,  investigators  using  identical  assays
ave  observed  a  similar  optimal  PR  cut-off  value  to  predict
hrombotic  events.  These  ﬁndings  suggest  a  threshold  of  PR
nhibition  associated  with  thrombotic  events.  A  consensus
as  therefore  been  proposed  to  deﬁne  high  on-treatment
latelet  reactivity  based  on  clinical  outcome  [1].  Platelet
eactivity  is  a  validated  biomarker  of  risk  of  early  stent
hrombosis.
Following  the  demonstration  of  a  strong  association
etween  PR  inhibition  and  outcome,  investigators  aimed
o  determine  if  PR  was  a  marker  of  risk  or  a  modiﬁable
isk  factor.  The  VASP  studies  were  among  the  ﬁrst  to  inves-
igate  the  clinical  impact  of  clopidogrel  dose-adjustment
ccording  to  PR  monitoring  in  patients  undergoing  PCI.  In
hese  studies,  a  signiﬁcant  reduction  in  1-month  major
dverse  cardiac  events  was  observed,  driven  largely  by  a
eduction  in  early  stent  thrombosis  in  patients  receiving
 tailored  antiplatelet  therapy  [7,8]. The  gauging  respon-
iveness  with  a  verifynow  assay-impact  on  thrombosis  and
afety  (GRAVITAS)  study  did  not  conﬁrm  these  prelimi-
ary  ﬁndings  [9].  There  are  several  explanations  for  this
isappointing  result:  the  inclusion  of  a  low-risk  popula-
ion,  lack  of  power,  insufﬁcient  therapeutic  strategy  in
ow  responders,  and  a  dose  adjustment  performed  after
CI  [9].  According  to  our  ﬁndings  of  improved  outcome
ith  optimal  PR  inhibition,  the  trial  to  assess  improvement
n  therapeutic  outcomes  by  optimizing  platelet  inhibi-
ion  with  prasugrel—thrombolysis  in  myocardial  infarction
TRITON—TIMI),  38  trial  demonstrated  a  signiﬁcant  reduction
n  major  adverse  cardiac  events  with  prasugrel  compared
ith  clopidogrel  in  patients  with  an  acute  coronary  syn-
rome  undergoing  PCI.  Prasugrel  is  a  third-generation
hienopyridine,  with  a  faster  and  stronger  biological  efﬁcacy
ompared  with  clopidogrel  but  similar  active  metabo-
ites  [10]. We  recently  observed  that  in  patients  receiving
rasugrel,  high  on-treatment  PR,  as  deﬁned  with  the
bove-mentioned  cut-off  value,  was  associated  with  a  poor
utcome,  further  validating  PR  as  a  biomarker  of  throm-
otic  events  following  PCI  [11]. The  role  of  this  biomarker
o  optimize  therapy  requires  a  large  randomized  trial  ade-
uately  testing  an  early  and  efﬁcient  therapeutic  strategy
c
c
m
wL.  Bonello  et  al.
o overcome  high  on-treatment  PR.  Such  trial  is  currently
acking.
ole of the endothelium in intimal
yperplasia
he  development  of  in-stent  restenosis  is  currently  a  major
imitation  of  PCI  using  bare-metal  stents.  The  primary
vent  leading  to  intimal  hyperplasia  is  loss  of  endothelial
ntegrity  induced  by  vascular  injury.  This  endothelial  dam-
ge  initiates  a  cascade  of  events,  including  smooth  muscle
ell  proliferation  and  migration,  leading  to  intimal  hyper-
lasia.  Indeed,  endothelial  cells  located  at  the  interface
etween  blood  and  tissues  are  plastic  cells  able  to  integrate
ignals  from  blood  or  surrounding  tissues.  By  developing
daptive  responses  they  critically  participate  in  the  main-
enance  of  vascular  homeostasis  through  their  capacity  to
revent  activation  of  haemostasis,  inﬂammatory  responses
nd  smooth  muscle  cell  proliferation.  Uncontrolled  acti-
ation  or  loss  of  physical  integrity  of  the  endothelial
onolayer  leads  to  endothelial  dysfunction  or  injury,  which
ritically  determines  initiation  and  progression  of  vascu-
ar  diseases.  Although  the  pathophysiological  importance  of
he  endothelium  is  widely  recognized,  this  organ  has  long
een  inaccessible  for  non-invasive  exploration.  Recently,
mprovement  in  understanding  of  the  endothelial  dynamics
as  led  to  the  identiﬁcation  of  endothelium-derived  compo-
ents  in  the  peripheral  blood,  providing  original  biomarkers
or  the  assessment  of  the  endothelial  integrity  in  clinical
ractice.  As  a  result  of  activation  or  apoptotic  processes,
essel  wall  endothelial  cells  shed  microparticles  or  became
etached,  leading  to  the  presence  of  circulating  endothe-
ial  cells  in  the  peripheral  blood.  Circulating  endothelial
ells  can  be  enumerated  using  a  standardized  CD146-based
mmunomagnetic  separation  assay  and  constitute  a  reliable
arker  of  endothelial  injury  with  diagnosis  and  prognos-
ic  value  in  various  cardiovascular  settings.  They  can  also
ehave  as  effective  factors  modulating  vascular  homeosta-
is  due  to  their  capacity  to  disseminate  proinﬂammatory  and
rocoagulant  signals  in  the  bloodstream  [12]. More  recently,
he  endothelial  response  to  injury  has  been  enlarged  by
he  discovery  of  powerful  repair  mechanism  involving  bone-
arrow-derived  EPC.  First  described  by  Ashara  et  al.  [3],
hese  cells  are  identiﬁed  among  CD34+  circulating  pro-
enitors  with  respect  to  their  ability  to  proliferate  and
ifferentiate  in  vitro  into  functional  endothelial  cells  and
o  actively  contribute  to  endothelial  repair  or  growth  when
ecruited  at  the  sites  of  endothelial  injury  or  ischemia  in
ivo.  EPC  are  now  recognized  as  a  heterogeneous  population
f  cells  originating  from  various  potential  tissue  reservoirs
nd  differentiation  lineage.  This  heterogeneity  allows  the
ain  distinction  of  cells  from  myeloid  lineage  that  sup-
orts  angiogenesis  through  paracrine  activities  and  ‘true’
ngioblasts,  of  non-haematopoietic  origin,  which  display
peciﬁc  ability  to  incorporate  into  healing  or  growing  ves-
els.  Although  the  exact  phenotype  of  EPC  is  still  a  matter  of
ebate,  clinical  studies  have  documented  increased  levels  of
irculating  EPC  following  ischaemia  or  endothelial  injury.  By
ontrast,  lower  levels  of  EPC  are  representative  of  a  compro-
ised  endothelial  repair  potential  and  may  identify  patients
ith  a  poor  cardiovascular  outcome  [13]. In  the  speciﬁc
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context  of  arterial  injury,  experimental  models  strongly  sup-
port  the  contribution  of  bone-marrow-derived  progenitors
to  early  re-endothelialization.  Moreover,  infusion  of  exoge-
nous  EPC  and  mobilization  of  endogeneous  EPC  are  effective
strategies  for  increasing  EPC  availability  in  the  blood,  result-
ing  in  early  re-endothelialization,  which  translates  into  the
prevention  of  vascular  remodelling  and  neointimal  forma-
tion  [14]. However,  despite  these  encouraging  ﬁndings  some
controversies  remain.  Animal  experiments  have  indicated
that  among  progenitor  cells  mobilized  from  bone  marrow
after  vascular  injury,  some  have  the  capacity  to  differen-
tiate  into  neointimal  smooth  muscle  cells.  In  addition,  the
impact  of  mobilizing  drugs  is  dependent  on  their  selectiv-
ity  for  EPC.  To  date,  human  studies  suggested  that  EPC
deﬁciency  may  be  associated  with  in-stent  restenosis  [15].
However  the  retrospective  design  of  the  studies  and  the  het-
erogeneity  in  methods  used  for  EPC  assessment  do  not  allow
a  deﬁnite  conclusion.  In  our  recent  studies,  we  evidenced
that  circulating  endothelial  cells  behave  as  a  promising
marker  of  PCI-induced  endothelial  injury,  integrating  not
only  the  mechanical  trauma  associated  with  the  procedure
but  also  an  individual  susceptibility  for  vessel  wall  injury
response  [16]. Interestingly,  among  factors  determining  the
extent  of  circulating  endothelial  cell  increase  following
PCI,  we  identiﬁed  the  role  of  platelet  reactivity.  Indeed,
an  optimal  control  of  clopidogrel-induced  P2Y12  blockade
(as  evidenced  by  the  VASP  index)  independently  predicted
reduced  endothelial  injury  consistent  with  its  endothelial
protective  impact  [17]. Collectively,  these  data  suggest
that  endothelial  dynamics  play  a  crucial  role  in  the  patho-
physiology  of  angioplasty-associated  vascular  complications,
including  in-stent  restenosis.  In  addition,  the  available  liter-
ature  regarding  the  role  of  EPC  in  early  re-endothelialization
of  vascular  injury  and  reduced  neointimal  hyperplasia  for-
mation  in  animal  models  suggests  that  EPC  could  be  a
biomarker  of  in-stent  restenosis  in  humans.  This  hypothesis
should  be  tested  in  a  prospective  trial.
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